ZEPOSIA® (ozanimod), a Sphingosine 1-Phosphate Receptor Modulator for Relapsing Forms of Multiple Sclerosis

This publication was sponsored and written in partnership with Bristol Myers Squibb.

This Clinical Brief provides key information on sphingosine 1-phosphate receptor modulators for relapsing forms of multiple sclerosis (MS), including results from the phase 3 SUNBEAM and RADIANCE trials for ZEPOSIA^® (ozanimod). An interview with Dr Jeffrey English, MD, of the Multiple Sclerosis Center of Atlanta offers insights on the evolution of treatments for MS, access to treatment, and disease management.